Step 1 Immunology
Immunology on USMLE Step 1 covers innate and adaptive immunity, hypersensitivity reactions, immunodeficiencies, transplant rejection, and immunosuppressive drugs. Questions range from pure mechanism (complement pathway triggers, MHC loading steps) to clinical vignettes where you diagnose a deficiency from an infection pattern or identify a hypersensitivity type from presentation timing and immunofluorescence findings. For anyone studying high-yield immunology for Step 1, hypersensitivity types and immunodeficiency syndromes are the two clusters that appear most frequently.
The most heavily tested clusters are the four hypersensitivity types, the immunodeficiency syndromes, and cytokine/T cell biology. Students consistently confuse Type II and Type III hypersensitivity because both involve IgG and complement — the key is whether antibody targets a fixed cell-surface antigen (Type II, linear immunofluorescence) or a floating immune complex (Type III, granular immunofluorescence). Immunodeficiency questions give you an infection pattern or lab finding and expect you to pinpoint the broken step in the immune circuit.
What makes USMLE immunology hard is the density of overlapping concepts: complement levels drop in both SLE and hereditary angioedema, but for opposite reasons — consumption versus inhibitor deficiency. Another common misconception: students treat hereditary angioedema as a histamine-driven process, when it is actually bradykinin-mediated, which is why antihistamines and epinephrine do not work. CD4 T cells are central to B cell help, Th subset biology, and HIV pathophysiology simultaneously, and the exam exploits these overlaps in Step 1 immunology questions constantly.
Thymus and T Cell Maturation
Positive selection in cortex vs negative selection in medulla — and what AIRE loss does to tolerance.
- Reverses the cortex vs medulla roles in positive and negative selection
- Confuses death by neglect (failed positive selection) with clonal deletion (failed negative selection)
Spleen Architecture and Function
Asplenic patients die from encapsulated bacteria; Howell-Jolly bodies and white vs red pulp functions tested here.
- Confuses white pulp (immune function) with red pulp (filtration/RBC removal)
- Misidentifies the organisms most dangerous to asplenic patients as intracellular rather than encapsulated bacteria
Lymph Node and MALT Architecture
Paracortex expands in viral infections; follicles expand with chronic antigen — zone-to-cell-type mapping matters.
- Confuses B cell follicles with T cell paracortex in lymph node architecture
- Confuses paracortex expansion (viral/T cell) with follicular expansion (B cell/chronic antigen)
Innate Immune Cells Overview
Dendritic cells prime naive T cells; neutrophils arrive first; M1 vs M2 polarization drives very different outcomes.
- Confuses neutrophils (first responders) with macrophages in the timeline of acute inflammation
- Reverses the cytokine triggers for M1 vs M2 macrophage polarization
NK Cells and Missing-Self
Missing MHC I activates NK killing — the inverse logic of CD8 T cells, with CD16 driving ADCC.
- Inverts the missing-self logic: MHC I inhibits NK killing rather than triggering it
- Misses the complementary logic: CD8 T cells require MHC I while NK cells are activated by its absence
Complement Pathways
Classical requires antibody; lectin recognizes mannose; alternative is always on — know which triggers which.
- Confuses the classical pathway (requires antibody) with innate pathways that act without antibody
- Incorrectly attributes the lectin pathway trigger to IgM rather than mannose-binding lectin
Complement Functions and Regulation
C3 deficiency means broad encapsulated risk; MAC deficiency means Neisseria only; PNH vs hereditary angioedema differ mechanistically.
- Fails to distinguish C3 deficiency (broad encapsulated bacteria risk) from MAC deficiency (Neisseria-specific risk)
- Reverses the relative potency of C3a vs C5a as anaphylatoxins
Toll-Like Receptors and Pattern Recognition
TLR4 binds LPS and triggers the cytokine storm responsible for septic shock — not direct LPS toxicity.
- Confuses TLR4 (LPS) with TLR5 (flagellin) in PAMP-to-TLR mapping
- Attributes septic shock directly to LPS rather than to the downstream cytokine storm it triggers via TLR4
Interferons
Type I interferons come from infected cells; IFN-gamma activates macrophages and is downstream of IL-12 in granuloma formation.
- Misattributes type I interferon production to T cells rather than virally infected cells and plasmacytoid dendritic cells
- Confuses IL-12 (upstream inducer) with IFN-gamma (direct macrophage activator) in granuloma formation
Acute Phase Reactants
IL-6 drives hepatic acute phase proteins and hepcidin, sequestering iron and causing anemia of chronic disease.
- Misidentifies TNF-alpha rather than IL-6 as the primary driver of hepatic acute phase reactant production
- Misclassifies albumin and transferrin as positive rather than negative acute phase reactants
Key Cytokines (Hot/Cold Map)
IL-12 and IFN-gamma drive Th1; IL-4 drives Th2; IL-10 suppresses; IL-17 defends barriers against fungi and extracellular bacteria.
- Confuses the source of IL-12 as T cells rather than innate antigen-presenting cells
- Confuses IL-10 as pro-inflammatory rather than the key immunosuppressive cytokine
MHC Class I and II
All nucleated cells express MHC I for CD8; APCs express MHC II for CD4 — cross-presentation bridges the gap.
- Confuses MHC I expression as restricted to APCs rather than all nucleated cells
- Reverses the MHC class–T cell subset pairing (CD4 with MHC I, CD8 with MHC II)
T Cell Activation and Costimulation
Signal 2 absence causes anergy not death; CTLA-4 and PD-1 are distinct checkpoints exploited by different immunotherapy drugs.
- Confuses T cell anergy (functional unresponsiveness) with apoptosis when costimulation is absent
- Conflates CTLA-4 and PD-1 as interchangeable checkpoints without recognizing their distinct anatomical and temporal roles
T Helper Subsets and Treg
FoxP3 loss causes IPEX — autoimmunity, not infection susceptibility; each Th subset has a signature cytokine output and inducing signal.
- Reverses the polarizing cytokines for Th1 and Th2 lineages
- Confuses FoxP3 (Treg master TF) with RORγt (Th17 master TF)
B Cell Activation, Class Switching, Somatic Hypermutation
AID drives class switching and somatic hypermutation in germinal centers; RAG handles V(D)J recombination and its loss causes SCID.
- Confuses RAG enzymes with AID as the enzyme responsible for class switching and somatic hypermutation
- Assumes T-independent antigens can drive class switching, which requires CD40L–CD40 T cell help
Immunoglobulin Structure and Isotypes
IgG crosses the placenta; secretory IgA dominates breast milk; IgM's high avidity comes from multivalency, not affinity maturation.
- Confuses IgM's high avidity (multivalency) with high affinity, which actually belongs to affinity-matured IgG
- Confuses placental transfer (IgG) with breast milk secretion (secretory IgA)
Antigen Processing and Presentation
Cytosolic antigens load onto MHC I via TAP in the ER; endocytic antigens load onto MHC II in the lysosome after invariant chain removal.
- Omits the TAP transporter step required to move cytosolic peptides into the ER for MHC I loading
- Confuses MHC II peptide loading as occurring in the ER rather than in the endolysosomal compartment after invariant chain removal
Type I Hypersensitivity (IgE / Immediate)
Sensitization on first exposure produces no symptoms; re-exposure cross-links IgE on mast cells — epinephrine is first-line, not antihistamines.
- Confuses sensitization (first exposure, no symptoms) with the re-exposure that triggers anaphylaxis
- Prioritizes antihistamines over epinephrine as first-line anaphylaxis treatment
Type II Hypersensitivity (Antibody vs Fixed Antigen)
Antibody targets fixed cell-surface antigens; Graves' uses a stimulating autoantibody, not a blocking one — complement plus ADCC plus opsonization all operate here.
- Confuses Goodpasture (linear IF, fixed antigen, Type II) with PSGN (granular IF, immune complex, Type III)
- Assumes all receptor-targeting autoantibodies are blocking, missing the stimulating autoantibody mechanism in Graves' disease
Type III Hypersensitivity (Immune Complex)
Immune complexes deposit and activate complement anaphylatoxins, recruiting neutrophils — serum sickness onset at 7–10 days distinguishes it from Type I.
- Attributes Type III tissue injury to direct MAC lysis rather than neutrophil-mediated damage triggered by complement anaphylatoxins
- Confuses the delayed 7–10 day onset of serum sickness with the immediate reaction of Type I hypersensitivity
Type IV Hypersensitivity (T Cell / Delayed)
No antibody involved — T cells drive the 48–72 hour delayed response seen in PPD testing, contact dermatitis, and granulomatous disease.
- Incorrectly attributes antibody involvement to Type IV hypersensitivity
- Confuses a negative PPD with definitive absence of TB exposure, missing anergy as a cause of false negatives
Hypersensitivity Overview and Discrimination
Fixed antigen equals Type II (linear IF); floating complex equals Type III (granular IF) — both use IgG and complement but differ here.
- Misassigns effector mechanisms to hypersensitivity types when using the ACID mnemonic
- Confuses Type II and Type III hypersensitivity because both use IgG and complement, missing the fixed vs. floating antigen distinction
Central and Peripheral Tolerance
Central tolerance deletes or edits self-reactive lymphocytes; peripheral tolerance anergizes or suppresses survivors — AIRE loss breaks the first layer.
- Misplaces negative selection to the thymic cortex instead of the medulla
- Assumes peripheral tolerance eliminates autoreactive T cells rather than suppressing or inactivating them
B Cell Deficiencies
XLA presents after 6 months when maternal IgG wanes; Hyper-IgM reflects CD40L failure, not a B cell production defect.
- Expects XLA to present at birth, not recognizing the protective role of maternal IgG in the first 6 months
- Underemphasizes the anaphylactic transfusion risk in selective IgA deficiency relative to infection risk
T Cell and Combined Deficiencies (DiGeorge, SCID, Wiskott-Aldrich, Ataxia-Telangiectasia)
DiGeorge is a pharyngeal pouch development failure; SCID needs a cause (ADA, γc chain); Wiskott-Aldrich has microthrombocytes as a key distinguishing lab.
- Misattributes DiGeorge to a lymphocyte defect rather than a pharyngeal pouch developmental failure
- Overlooks ADA deficiency as a major cause of SCID, focusing only on γc chain mutations
Phagocyte Deficiencies (CGD, LAD, Chediak-Higashi, Job)
CGD kills only with catalase-positive organisms; LAD presents with delayed cord separation and absent pus; Chediak-Higashi has giant granules and partial albinism.
- Fails to recognize that CGD susceptibility is restricted to catalase-positive organisms
- Confuses Chediak-Higashi with CGD, missing the lysosomal trafficking defect and giant granule morphology
Complement Deficiencies
Hereditary angioedema runs on bradykinin not histamine; C3 deficiency broadens infection risk; terminal complement defects predispose specifically to Neisseria.
- Confuses hereditary angioedema with allergic angioedema, missing the bradykinin (not histamine) mechanism
- Conflates C3 deficiency and MAC deficiency infection patterns, missing Neisseria specificity of terminal complement defects
HIV Immunology
HIV requires CD4 plus a co-receptor (CCR5 or CXCR4); CD4 count thresholds are staggered across opportunistic infections, not a single cutoff.
- Overlooks the obligatory co-receptor (CCR5 or CXCR4) required for HIV cell entry alongside CD4
- Overgeneralizes CCR5-delta32 protection to all HIV strains, missing residual X4 susceptibility
Vaccine Types and Contraindications
Live attenuated vaccines are contraindicated in pregnancy and immunocompromised states; subunit vaccines need adjuvants to activate innate immunity.
- Restricts live vaccine contraindication to T cell deficiency, missing other immunocompromised states and pregnancy
- Equates the immunogenicity of killed vaccines with live attenuated vaccines
Transplant Rejection (Hyperacute, Acute, Chronic, GVHD)
Hyperacute occurs within minutes from pre-formed antibodies; chronic rejection is a distinct fibroproliferative vasculopathy, not accumulated acute episodes.
- Confuses hyperacute rejection timing with acute rejection, missing the minutes-to-hours onset from pre-formed antibodies
- Applies antibody-mediated rejection treatment (plasmapheresis) to acute cellular rejection
Calcineurin Inhibitors and mTOR Inhibitors
Cyclosporine binds cyclophilin; tacrolimus binds FKBP12 — both block calcineurin and IL-2 production; nephrotoxicity belongs to these, not sirolimus.
- Confuses the intracellular binding proteins for cyclosporine vs. tacrolimus
- Confuses sirolimus mechanism (IL-2 signaling) with calcineurin inhibitor mechanism (IL-2 production)
Antiproliferative Immunosuppressants
Mycophenolate blocks IMPDH; azathioprine becomes 6-MP — allopurinol dangerously raises azathioprine toxicity by blocking xanthine oxidase.
- Confuses the distinct purine synthesis steps targeted by mycophenolate vs. azathioprine
- Misses the dangerous interaction between allopurinol and azathioprine via xanthine oxidase inhibition
Biologic Immunosuppressants and Monoclonal Antibodies
Rituximab targets CD20 on B cells; basiliximab blocks IL-2R; TNF inhibitors require latent TB screening before use.
- Confuses basiliximab (IL-2R blocker) with ATG (T-cell depleting agent)
- Confuses rituximab's B-cell (CD20) target with a T-cell target
See how your Anki deck covers Immunology.
Upload your deck for a free audit →